Buckley Mortimer J, a Director, purchased 37,632 shares of common stock at $25.52 per share for a total purchase amount of $960,368 and after the transaction directly owns 37,632 shares of common stock.Ronald E. Blaylock, a Director, purchased 39,231 shares of common stock at $25.46 per share for a…
Pfizer, Merck and Amgen outlined plans to expand their cancer portfolios as part of their earnings on Tuesday, fueling more speculative retail chatter around smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX).Pfizer Targets Cancer Growth With PadcevPfizer called oncol…
Q2 2026 saw $15B in revenue (up 1% YoY), with strong non-COVID growth and adjusted EPS of $0.77. Full-year guidance was raised, cost savings initiatives expanded, and key pipeline assets in oncology, obesity, and immunology advanced. Dividend commitment remains firm.Based on Pfizer, Inc. [PFE] Q2 2…
Pfizer Inc reported results for the 2026 quarter with revenue of $15.03B, a year-over-year rise of 2.6%, while net income swung to a loss of ($248M) and diluted EPS was ($0.04), compared with $2.91B and $0.51, respectively, in the prior-year quarter.Financial Highlights¹ Reported as “Total revenues…
Q2 2026 revenue rose 1% YoY to $15.0B, with adjusted EPS at $0.77, reflecting higher R&D spend but strong growth from new and acquired products. 2026 revenue guidance midpoint was raised to $61.5B, with robust pipeline progress and $9.7B in targeted cost savings through 2029.Original document: Pfiz…
Pfizer Inc. (NYSE:PFE) is navigating widening patent battles over mRNA and lipid‑nanoparticle COVID vaccine technology—from suits in Canada, the EU and expanded U.S. litigation to a BioNTech countersuit—while also pausing Premarin vaginal cream distribution in India amid supply disruptions.Previous…
Vertex Pharmaceuticals NASDAQ:VRTX has agreed to buy Crinetics Pharmaceuticals NASDAQ:CRNX for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical…
Pfizer Inc NYSE:PFE:
By Michael Erman and Deena BeasleyPresident Donald Trump has promised to make U.S. prescription drug prices the cheapest in the world, but a closely watched Medicaid pilot program could expose the limits of the buy-in among mid-sized and smaller pharmaceutical companies.The administration convinced…
By Mike ScarcellaA group of public health professionals, scientists and others that sued the U.S. Food and Drug Administration to obtain COVID-19 vaccine approval records has asked a federal judge to order the government to pay more than $867,000 in legal fees and costs.Public Health and Medical Pr…
Pfizer's NYSE:PFE ecnoglutide and Innovent Biologics' HKEX:1801 mazdutide have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a list published by the National Healthcare Security Administration showed on Monday.The two drugs, which belong t…
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a a list published by the National Healthcare Security Administration showed on Monday.
